MiMedx Group, Inc (NASDAQ:MDXG) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of MiMedx Group, Inc (NASDAQ:MDXG) have earned an average recommendation of “Moderate Buy” from the seven ratings firms that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation and six have assigned a buy recommendation to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $8.50.

Several research firms have recently weighed in on MDXG. Citizens Jmp decreased their price objective on shares of MiMedx Group from $7.00 to $6.00 and set a “market outperform” rating for the company in a research report on Thursday, April 30th. Craig Hallum reduced their price target on shares of MiMedx Group from $10.00 to $7.00 and set a “buy” rating for the company in a report on Friday, April 17th. Weiss Ratings cut shares of MiMedx Group from a “sell (d+)” rating to a “sell (d)” rating in a report on Monday, May 18th. Wall Street Zen cut shares of MiMedx Group from a “buy” rating to a “hold” rating in a report on Saturday, May 2nd. Finally, UBS Group set a $10.00 price target on shares of MiMedx Group in a report on Monday, February 23rd.

Institutional Investors Weigh In On MiMedx Group

A number of large investors have recently bought and sold shares of MDXG. Sunbelt Securities Inc. acquired a new stake in MiMedx Group in the first quarter worth $42,000. Kemnay Advisory Services Inc. acquired a new stake in MiMedx Group in the fourth quarter worth $48,000. Y Intercept Hong Kong Ltd acquired a new stake in MiMedx Group in the first quarter worth $65,000. Headlands Technologies LLC acquired a new stake in MiMedx Group in the second quarter worth $72,000. Finally, Jain Global LLC acquired a new stake in MiMedx Group in the fourth quarter worth $73,000. 79.15% of the stock is currently owned by institutional investors and hedge funds.

MiMedx Group Trading Up 0.3%

MDXG opened at $3.71 on Wednesday. MiMedx Group has a twelve month low of $3.03 and a twelve month high of $7.99. The company has a quick ratio of 4.81, a current ratio of 5.39 and a debt-to-equity ratio of 0.07. The company has a fifty day moving average of $3.64 and a 200-day moving average of $4.98. The stock has a market cap of $552.60 million, a PE ratio of 18.55 and a beta of 1.48.

MiMedx Group (NASDAQ:MDXG) last posted its quarterly earnings data on Wednesday, April 29th. The company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.02. MiMedx Group had a net margin of 7.88% and a return on equity of 21.03%. The company had revenue of $58.99 million during the quarter, compared to analysts’ expectations of $65.80 million. On average, sell-side analysts predict that MiMedx Group will post -0.01 EPS for the current year.

MiMedx Group Company Profile

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.